Skip to content
Research Article Open access CC BY 4.0

Progress in HIV-1 Prevention, Control and Treatment: Genetic Manipulation or Pharmacological Blockade of Chemokine Receptor 5?

Abdullahi Ibrahim Uba, Gonca Dilcan, Sani Sharif Usman

Journal of Advances in Biology & Biotechnology · pp. 1–9 · Published 16 Jun 2016

10.9734/JABB/2016/26768

Abstract

For Human immunodeficiency virus type 1 (HIV-1) to invade the host cells it requires human cluster of differentiation (CD4) receptor and a chemokine receptor, principally chemokine receptor 5 (CCR5). Although the viral particles interact with several receptors on cell surface, a key receptor, CD4 and a co-receptor act in succession to facilitate the fusion of the viral glycoprotein with cellular membranes allowing the entry of the virus into cells. The CCR5 is the predominant co-receptor for HIV-1. HIV-1 is the most common pathogenic strain and its genetic hyper-variability makes the virus resistant to antiretroviral drug therapy. Current approaches focus on the CCR5 as the emerging target for HIV-1 control. Here, we highlight the current trend in HIV-1 control, prevention and treatment, compare the two promising approaches: Genetic manipulation of CCR5 gene and the pharmacological blockade of CCR5 using chemokine receptor antagonists.  

HIV-1 CCR5 genetic manipulation CCR5 blockade

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.